This article is more than 5 years old. Information may no longer be current.
Graves' disease, toxic nodular goiter associated with increased risk for mortality
Click Here to Manage Email Alerts
Risk for all-cause mortality appears to be higher for patients with Graves’ disease or toxic nodular goiter when treated in a hospital setting, new research suggests.
"The causes of death differ between the two phenotypes, with cardiovascular mortality being significantly higher in Graves' disease," Frans Brandt, MD, from the department of endocrinology and metabolism at Odense University Hospital in Denmark, and colleagues wrote.
For the observational cohort study, researchers used record-linkage data from nationwide Danish health registers. The cohort included 1,291 patients with Graves' disease and 861 with toxic nodular goiter treated in a hospital setting. Researchers followed patients for an average of 11 years.
Researchers found that Graves' disease (HR=1.42; 95% CI, 1.25-1.6) and toxic nodular goiter (HR=1.22; 95% CI, 1.07-1.4) were both associated with all-cause mortality.
According to researchers, Graves' disease was also associated with increased mortality due to cardiovascular diseases (HR=1.49; 95% CI, 1.25-1.77) and lung diseases (HR=1.91; 95% CI, 1.37-2.65) after stratification for cause of death. Toxic nodular goiter was associated with increased cancer mortality (HR=1.36; 95% CI, 1.06-1.75).
Researchers did not find a significant difference in all-cause mortality between Graves' disease and toxic nodular goiter. However, Graves' disease was associated with a higher CV mortality than toxic nodular goiter (HR=1.39; 95% CI, 1.1-1.76).
Disclosure: The researchers report no relevant financial disclosures.
Click Here to Manage Email Alerts